Envelope residue 375 substitutions in simian–human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques
Open accessThe DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Significance: Simian–human immunodeficiency viruses (SHIVs) are an invaluable tool for assessing HIV-1 vaccines, developing therapeutic “cure” strategies, and understanding viral immunopathogenesis. However, only limited success has been achieved in creating SHIVs that incorporate HIV-1 envelopes (Envs) that retain the antigenic features of clinically relevant viruses. Here we focus on a critical residue of the CD4-binding region, Env375, which is under strong positive selection across the broad range of primate lentiviruses. We find that genotypic variation of residue 375 allows for the creation of pathogenic SHIVs that retain the antigenicity, tier 2 neutralization sensitivity, and persistence properties characteristic of primary HIV-1 strains. Taken together, our findings suggest a new paradigm for SHIV design and modeling with important applications to HIV-1 vaccine, cure, and pathogenesis research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clustal W and Clustal X version 2.0
Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., et al. (2007) · Bioinformatics · doi:10.1093/bioinformatics/btm404 · Cited by 28,358
Guindon, S., Dufayard, J.-F., Lefort, V., Anisimova, M., Hordijk, W., & Gascuel, O. (2010) · Systematic Biology · doi:10.1093/sysbio/syq010 · Cited by 18,376
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Kwong, P. D., Wyatt, R., Robinson, J., Sweet, R. W., Sodroski, J., & Hendrickson, W. A. (1998) · Nature · doi:10.1038/31405 · Cited by 2,964 · cited 4×
“This process creates a ∼150-Å(3) cavity between HIV-1 gp120 and CD4 bounded by Phe-43 of CD4, which makes numerous contacts with conserved gp120 residues, although Env375 is not one of them (48, 85).”
BackgroundInfluentialSelf-citationAntibody neutralization and escape by HIV-1
Wei, X., Decker, J. M., Wang, S., Hui, H., Kappes, J. C., Wu, X., Salazar-Gonzalez, J. F., Salazar, M. G., Kilby, J. M., Saag, M. S., et al. (2003) · Nature · doi:10.1038/nature01470 · Cited by 2,421 · cited 2×
“SHIV entry was assessed in primary activated human and rhesus CD4 T cells and in cell lines expressing huCD4 and huCCR5 [TZM-bl cells (61, 94)] or rhCD4 and rhCCR5 (ZB5 cells) (SI Materials and Methods).”
MethodSelf-citationKeele, B. F., Giorgi, E. E., Salazar-Gonzalez, J. F., Decker, J. M., Pham, K. T., Salazar, M. G., Sun, C., Grayson, T., Wang, S., Li, H., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802203105 · Cited by 1,912 · cited 3×
“Specifically, they exhibit sensitivity to a wide spectrum of broadly neutralizing mAbs that target the five principal sites of bNAb recognition (77, 78), while retaining effective conformational masking typical of primary or T/F virus strains (23, 65).”
BackgroundMethodSelf-citationWei, X., Decker, J. M., Liu, H., Zhang, Z., Arani, R. B., Kilby, J. M., Saag, M. S., Wu, X., Shaw, G. M., & Kappes, J. C. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1896-1905.2002 · Cited by 1,569 · cited 3×
“SHIV entry was assessed in primary activated human and rhesus CD4 T cells and in cell lines expressing huCD4 and huCCR5 [TZM-bl cells (61, 94)] or rhCD4 and rhCCR5 (ZB5 cells) (SI Materials and Methods).”
MethodSelf-citationFiebig, E. W., Wright, D. J., Rawal, B. D., Garrett, P. E., Schumacher, R. T., Peddada, L., Heldebrant, C., Smith, R., Conrad, A., Kleinman, S. H., et al. (2003) · AIDS · doi:10.1097/00002030-200309050-00005 · Cited by 1,305 · cited 1×
“Western blot immunoreactivity to core and Env proteins was assessed at 4 and 10 wk after infection, corresponding to a time frame that in humans is associated with anti–HIV-1 antibody seroconversion (68).”
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Self-citationMOLPROBITY: structure validation and all-atom contact analysis for nucleic acids and their complexes
Davis, I. W., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh398 · Cited by 1,030
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
Liao, H.-X., Lynch, R., Zhou, T., Gao, F., Alam, S. M., Boyd, S. D., Fire, A. Z., Roskin, K. M., Schramm, C. A., Zhang, Z., et al. (2013) · Nature · doi:10.1038/nature12053 · Cited by 988
Self-citationA Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells
Campeau, E., Ruhl, V. E., Rodier, F., Smith, C. L., Rahmberg, B. L., Fuss, J. O., Campisi, J., Yaswen, P., Cooper, P. K., & Kaufman, P. D. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006529 · Cited by 964
Sanders, R. W., Derking, R., Cupo, A., Julien, J.-P., Yasmeen, A., de Val, N., Kim, H. J., Blattner, C., de la Peña, A. T., Korzun, J., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003618 · Cited by 935
Fc receptor but not complement binding is important in antibody protection against HIV
Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E. G., Beurskens, F. J., Bakker, J. M., Lanigan, C. M. S., Landucci, G., Forthal, D. N., Parren, P. W. H. I., et al. (2007) · Nature · doi:10.1038/nature06106 · Cited by 901
Kwong, P. D., Doyle, M. L., Casper, D. J., Cicala, C., Leavitt, S. A., Majeed, S., Steenbeke, T. D., Venturi, M., Chaiken, I., Fung, M., et al. (2002) · Nature · doi:10.1038/nature01188 · Cited by 889 · cited 2×
“Specifically, they exhibit sensitivity to a wide spectrum of broadly neutralizing mAbs that target the five principal sites of bNAb recognition (77, 78), while retaining effective conformational masking typical of primary or T/F virus strains (23, 65).”
BackgroundSelf-citationCrystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer
Julien, J.-P., Cupo, A., Sok, D., Stanfield, R. L., Lyumkis, D., Deller, M. C., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., et al. (2013) · Science · doi:10.1126/science.1245625 · Cited by 797
Structural definition of a conserved neutralization epitope on HIV-1 gp120
Zhou, T., Xu, L., Dey, B., Hessell, A. J., Van Ryk, D., Xiang, S.-H., Yang, X., Zhang, M.-Y., Zwick, M. B., Arthos, J., et al. (2007) · Nature · doi:10.1038/nature05580 · Cited by 770 · cited 1×
“This process creates a ∼150-Å(3) cavity between HIV-1 gp120 and CD4 bounded by Phe-43 of CD4, which makes numerous contacts with conserved gp120 residues, although Env375 is not one of them (48, 85).”
BackgroundSelf-citationSalazar-Gonzalez, J. F., Salazar, M. G., Keele, B. F., Learn, G. H., Giorgi, E. E., Li, H., Decker, J. M., Wang, S., Baalwa, J., Kraus, M. H., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090378 · Cited by 764 · cited 2×
“Coreceptor use was determined in TZM-bl cells by selective blockade using Maraviroc (CCR5), AMD3100 (CXCR4), or a mixture of inhibitors (66) (SI Materials and Methods).”
MethodSelf-citationStructure and immune recognition of trimeric pre-fusion HIV-1 Env
Pancera, M., Zhou, T., Druz, A., Georgiev, I. S., Soto, C., Gorman, J., Huang, J., Acharya, P., Chuang, G.-Y., Ofek, G., et al. (2014) · Nature · doi:10.1038/nature13808 · Cited by 740 · cited 1×
“HIV-1 Env binding to the CD4 receptor involves multiple structural rearrangements as Env transitions from a prefusion closed state (45), through a single CD4-bound intermediate (46), to a more fully engaged Env trimer capable of recognizing the coreceptor (47).”
BackgroundSelf-citationCryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer
Lyumkis, D., Julien, J.-P., de Val, N., Cupo, A., Potter, C. S., Klasse, P.-J., Burton, D. R., Sanders, R. W., Moore, J. P., Carragher, B., et al. (2013) · Science · doi:10.1126/science.1245627 · Cited by 669
Barouch, D. H., Whitney, J. B., Moldt, B., Klein, F., Oliveira, T. Y., Liu, J., Stephenson, K. E., Chang, H.-W., Shekhar, K., Gupta, S., et al. (2013) · Nature · doi:10.1038/nature12744 · Cited by 644 · cited 1×
“SHIVs have been used to assess the protective effects of neutralizing or antibody-dependent cell-mediated cytotoxicity conferring antibodies (3–7), the elicitation of broadly neutralizing antibodies (bNAbs) (8–11), the efficacy of broadly neutralizing monoclonal antibodies (mAbs) in preclinical trials with suppressive…”
BackgroundSelf-citationSeaman, M. S., Janes, H., Hawkins, N., Grandpre, L. E., Devoy, C., Giri, A., Coffey, R. T., Harris, L., Wood, B., Daniels, M. G., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02108-09 · Cited by 632 · cited 2×
“Neutralization was assessed in TZM-bl cells by a standardized method (61, 70, 71, 94).”
MethodSelf-citationTomaras, G. D., Yates, N. L., Liu, P., Qin, L., Fouda, G. G., Chavez, L. L., Decamp, A. C., Parks, R. J., Ashley, V. C., Lucas, J. T., et al. (2008) · Journal of Virology · doi:10.1128/jvi.01708-08 · Cited by 631
Self-citationImmune clearance of highly pathogenic SIV infection
Hansen, S. G., Jr, M. P., Ventura, A. B., Hughes, C. M., Gilbride, R. M., Ford, J. C., Oswald, K., Shoemaker, R., Li, Y., Lewis, M. S., et al. (2013) · Nature · doi:10.1038/nature12519 · Cited by 597
Self-citationZamyatnin, A. A. (1972) · Progress in Biophysics and Molecular Biology · doi:10.1016/0079-6107(72)90005-3 · Cited by 593
Hessell, A. J., Poignard, P., Hunter, M., Hangartner, L., Tehrani, D. M., Bleeker, W. K., Parren, P. W. H. I., Marx, P. A., & Burton, D. R. (2009) · Nature Medicine · doi:10.1038/nm.1974 · Cited by 546
HIV-1 neutralizing antibodies induced by native-like envelope trimers
Sanders, R. W., van Gils, M. J., Derking, R., Sok, D., Ketas, T. J., Burger, J. A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. (2015) · Science · doi:10.1126/science.aac4223 · Cited by 496
Self-citationConformational dynamics of single HIV-1 envelope trimers on the surface of native virions
Munro, J. B., Gorman, J., Ma, X., Zhou, Z., Arthos, J., Burton, D. R., Koff, W. C., Courter, J. R., Smith, A. B., Kwong, P. D., et al. (2014) · Science · doi:10.1126/science.1254426 · Cited by 492 · cited 1×
“HIV-1 Env binding to the CD4 receptor involves multiple structural rearrangements as Env transitions from a prefusion closed state (45), through a single CD4-bound intermediate (46), to a more fully engaged Env trimer capable of recognizing the coreceptor (47).”
BackgroundSelf-citationB-cell–lineage immunogen design in vaccine development with HIV-1 as a case study
Haynes, B. F., Kelsoe, G., Harrison, S. C., & Kepler, T. B. (2012) · Nature Biotechnology · doi:10.1038/nbt.2197 · Cited by 486 · cited 1×
“In this way, analysis of virus–antibody coevolution can potentially guide structure-based (56, 90, 91) or viral lineage-based (92, 93) immunogen design.”
MethodSelf-citationVeazey, R. S., Shattock, R. J., Pope, M., Kirijan, J. C., Jones, J., Hu, Q., Ketas, T., Marx, P. A., Klasse, P. J., Burton, D. R., et al. (2003) · Nature Medicine · doi:10.1038/nm833 · Cited by 460 · cited 1×
“J Acquir Immune Defic Syndr 5(7):639–646.”
Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia
Shingai, M., Nishimura, Y., Klein, F., Mouquet, H., Donau, O. K., Plishka, R., Buckler-White, A., Seaman, M., Piatak, M., Lifson, J. D., et al. (2013) · Nature · doi:10.1038/nature12746 · Cited by 455 · cited 1×
“SHIVs have been used to assess the protective effects of neutralizing or antibody-dependent cell-mediated cytotoxicity conferring antibodies (3–7), the elicitation of broadly neutralizing antibodies (bNAbs) (8–11), the efficacy of broadly neutralizing monoclonal antibodies (mAbs) in preclinical trials with suppressive…”
BackgroundSelf-citationEnergetics of the HIV gp120-CD4 binding reaction
Myszka, D. G., Sweet, R. W., Hensley, P., Brigham-Burke, M., Kwong, P. D., Hendrickson, W. A., Wyatt, R., Sodroski, J., & Doyle, M. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.16.9026 · Cited by 422
Self-citationPhenotypic properties of transmitted founder HIV-1
Parrish, N. F., Gao, F., Li, H., Giorgi, E. E., Barbian, H. J., Parrish, E. H., Zajic, L., Iyer, S. S., Decker, J. M., Kumar, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304288110 · Cited by 422 · cited 1×
“These limitations are often related to properties of the envelope (Env), which in most SHIVs does not faithfully reflect primary HIV-1 strains or transmitted/founder (T/F) viruses (23, 24).”
BackgroundSelf-citationPriming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen
Jardine, J. G., Ota, T., Sok, D., Pauthner, M., Kulp, D. W., Kalyuzhniy, O., Skog, P. D., Thinnes, T. C., Bhullar, D., Briney, B., et al. (2015) · Science · doi:10.1126/science.aac5894 · Cited by 420 · cited 1×
“In this way, analysis of virus–antibody coevolution can potentially guide structure-based (56, 90, 91) or viral lineage-based (92, 93) immunogen design.”
MethodAntibody responses to envelope glycoproteins in HIV-1 infection
Burton, D. R., & Mascola, J. R. (2015) · Nature Immunology · doi:10.1038/ni.3158 · Cited by 385 · cited 1×
“Specifically, they exhibit sensitivity to a wide spectrum of broadly neutralizing mAbs that target the five principal sites of bNAb recognition (77, 78), while retaining effective conformational masking typical of primary or T/F virus strains (23, 65).”
BackgroundAbrahams, M.-R., Anderson, J. A., Giorgi, E. E., Seoighe, C., Mlisana, K., Ping, L.-H., Athreya, G. S., Treurnicht, F. K., Keele, B. F., Wood, N., et al. (2009) · Journal of Virology · doi:10.1128/jvi.02132-08 · Cited by 381
Self-citationLi, Y., Kappes, J. C., Conway, J. A., Price, R. W., Shaw, G. M., & Hahn, B. H. (1991) · Journal of Virology · doi:10.1128/jvi.65.8.3973-3985.1991 · Cited by 378 · cited 1×
“Complete tat–rev–vpu–env(gp160) cassettes from a prototypic primary subtype B strain YU2 (51) and from a genetically divergent T/F subtype D HIV-1 strain 191859 (52) were exchanged for the corresponding region of SIVmac766 (Fig.”
BackgroundSelf-citationDo Kwon, Y., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., Joyce, M. G., Guttman, M., Ma, X., Narpala, S., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3051 · Cited by 345 · cited 1×
“HIV-1 Env binding to the CD4 receptor involves multiple structural rearrangements as Env transitions from a prefusion closed state (45), through a single CD4-bound intermediate (46), to a more fully engaged Env trimer capable of recognizing the coreceptor (47).”
BackgroundSelf-citationBarouch, D. H., Stephenson, K. E., Borducchi, E. N., Smith, K., Stanley, K., McNally, A. G., Liu, J., Abbink, P., Maxfield, L. F., Seaman, M. S., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.061 · Cited by 342
Animal models for HIV/AIDS research
Hatziioannou, T., & Evans, D. T. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2911 · Cited by 340 · cited 1×
“S immunodeficiency viruses (SHIVs), which express the envelope of HIV-1 within the context of simian immunodeficiency virus of macaque (SIVmac) structural and regulatory elements, have broad potential applications for HIV/AIDS vaccine, treatment (cure), and pathogenesis research (1, 2).”
BackgroundSelf-citationPancera, M., Majeed, S., Ban, Y.-E. A., Chen, L., Huang, C.-C., Kong, L., Kwon, Y. D., Stuckey, J., Zhou, T., Robinson, J. E., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911004107 · Cited by 338 · cited 2×
“Structural and molecular biological studies have revealed a “layered” inner domain gp120 architecture that facilitates movement among alternative Env conformations required for virus entry (25, 50, 80, 84).”
BackgroundSelf-citationdeCamp, A., Hraber, P., Bailer, R. T., Seaman, M. S., Ochsenbauer, C., Kappes, J., Gottardo, R., Edlefsen, P., Self, S., Tang, H., et al. (2014) · Journal of Virology · doi:10.1128/jvi.02853-13 · Cited by 330 · cited 3×
“Neutralization was assessed in TZM-bl cells by a standardized method (61, 70, 71, 94).”
MethodSelf-citationStructural Insights on the Role of Antibodies in HIV-1 Vaccine and Therapy
West, A. P., Scharf, L., Scheid, J. F., Klein, F., Bjorkman, P. J., & Nussenzweig, M. C. (2014) · Cell · doi:10.1016/j.cell.2014.01.052 · Cited by 321 · cited 1×
“Specifically, they exhibit sensitivity to a wide spectrum of broadly neutralizing mAbs that target the five principal sites of bNAb recognition (77, 78), while retaining effective conformational masking typical of primary or T/F virus strains (23, 65).”
BackgroundDistinct Pathogenic Sequela in Rhesus Macaques Infected with CCR5 or CXCR4 Utilizing SHIVs
Harouse, J. M., Gettie, A., Tan, R. C. H., Blanchard, J., & Cheng-Mayer, C. (1999) · Science · doi:10.1126/science.284.5415.816 · Cited by 320 · cited 1×
“Proc Natl Acad Sci USA 97(16):9026–9031.”
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody
Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M. G., Ozorowski, G., Chuang, G.-Y., Schramm, C. A., Wiehe, K., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.022 · Cited by 319 · cited 3×
“, CD4bs bNAb lineages by HIV-1 CH505 (53, 55, 75) or V1/V2 bNAb lineages by HIV-1 CRF_AG_250, ZM233, WITO4160, and CAP256 (88, 89)] or to elicit bNAbs in humans [e.”
BackgroundSelf-citationAndré, S., Seed, B., Eberle, J., Schraut, W., Bültmann, A., & Haas, J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1497-1503.1998 · Cited by 305
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges
Gardner, M. R., Kattenhorn, L. M., Kondur, H. R., von Schaewen, M., Dorfman, T., Chiang, J. J., Haworth, K. G., Decker, J. M., Alpert, M. D., Bailey, C. C., et al. (2015) · Nature · doi:10.1038/nature14264 · Cited by 298
Self-citationAntigenic conservation and immunogenicity of the HIV coreceptor binding site
Decker, J. M., Bibollet-Ruche, F., Wei, X., Wang, S., Levy, D. N., Wang, W., Delaporte, E., Peeters, M., Derdeyn, C. A., Allen, S., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042510 · Cited by 295 · cited 1×
“Importantly, we observed that the V3 and CD4i mAbs (64) did not neutralize any of the wild type SHIVs or their Env375 variants aside from modest activity against B.”
BackgroundSelf-citationProspective study of acute HIV-1 infection in adults in East Africa and Thailand.
Robb, M. L., Eller, L. A., Kibuuka, H., Rono, K., Maganga, L., Nitayaphan, S., Kroon, E., Sawe, F. K., Sinei, S., Sriplienchan, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508952 · Cited by 283 · cited 2×
“5) were nearly indistinguishable from human infection by HIV-1 (72, 73).”
BackgroundNdhlovu, Z. M., Kamya, P., Mewalal, N., Kløverpris, H. N., Nkosi, T., Pretorius, K., Laher, F., Ogunshola, F., Chopera, D., Shekhar, K., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.08.012 · Cited by 282
Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies
Gao, F., Bonsignori, M., Liao, H.-X., Kumar, A., Xia, S.-M., Lu, X., Cai, F., Hwang, K.-K., Song, H., Zhou, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.022 · Cited by 279 · cited 3×
“, CD4bs bNAb lineages by HIV-1 CH505 (53, 55, 75) or V1/V2 bNAb lineages by HIV-1 CRF_AG_250, ZM233, WITO4160, and CAP256 (88, 89)] or to elicit bNAbs in humans [e.”
BackgroundSelf-citationHuang, C.-C., Venturi, M., Majeed, S., Moore, M. J., Phogat, S., Zhang, M.-Y., Dimitrov, D. S., Hendrickson, W. A., Robinson, J., Sodroski, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308527100 · Cited by 275
Self-citationWu, X., Parast, A. B., Richardson, B. A., Nduati, R., John-Stewart, G., Mbori-Ngacha, D., Rainwater, S. M. J., & Overbaugh, J. (2006) · Journal of Virology · doi:10.1128/jvi.80.2.835-844.2006 · Cited by 274 · cited 1×
“BG505, we modified residue Env332T, which corresponds to the wild-type T/F virus (57) (GenBank accession no.”
MethodImmunization for HIV-1 Broadly Neutralizing Antibodies in Human Ig Knockin Mice
Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N. T., Gitlin, A. D., McGuire, A. T., Kulp, D. W., Oliveira, T., Scharf, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.003 · Cited by 263 · cited 1×
“In this way, analysis of virus–antibody coevolution can potentially guide structure-based (56, 90, 91) or viral lineage-based (92, 93) immunogen design.”
MethodReimann, K. A., Li, J. T., Voss, G., Lekutis, C., Tenner‐Racz, K., Rácz, P., Lin, W., Montefiori, D. C., Lee‐Parritz, D. E., Lu, Y., et al. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3198-3206.1996 · Cited by 246 · cited 2×
“Proc Natl Acad Sci USA 109(15):5663–5668.”
BackgroundSelf-citationDimmic, M. W., Rest, J. S., Mindell, D. P., & Goldstein, R. A. (2002) · Journal of Molecular Evolution · doi:10.1007/s00239-001-2304-y · Cited by 243
Kwon, Y. D., Finzi, A., Wu, X., Dogo-Isonagie, C., Lee, L. K., Moore, L. R., Schmidt, S. D., Stuckey, J., Yang, Y., Zhou, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112391109 · Cited by 235
Self-citationFinzi, A., Xiang, S.-H., Pacheco, B., Wang, L., Haight, J., Kassa, A., Danek, B., Pancera, M., Kwong, P. D., & Sodroski, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.02.012 · Cited by 209 · cited 8×
“Thus, we conclude that the mechanism by which the different SHIV Env375 amino acid substitutions enhance rhCD4 binding is likely to be similar to that described for enhanced binding of the YU2 Env375W variant to human CD4 (25, 44, 50, 84).”
BackgroundResultInfluentialSelf-citationMicrovesicles Are a Source of Contaminating Cellular Proteins Found in Purified HIV-1 Preparations
Bess, J. W., Gorelick, R. J., Bosche, W. J., Henderson, L. E., & Arthur, L. O. (1997) · Virology · doi:10.1006/viro.1997.8499 · Cited by 206
Bhiman, J. N., Anthony, C., Doria-Rose, N. A., Karimanzira, O., Schramm, C. A., Khoza, T., Kitchin, D., Botha, G., Gorman, J., Garrett, N. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3963 · Cited by 199 · cited 1×
“In this way, analysis of virus–antibody coevolution can potentially guide structure-based (56, 90, 91) or viral lineage-based (92, 93) immunogen design.”
MethodSelf-citationAndrabi, R., Voss, J. E., Liang, C.-H., Briney, B., McCoy, L. E., Wu, C.-Y., Wong, C.-H., Poignard, P., & Burton, D. R. (2015) · Immunity · doi:10.1016/j.immuni.2015.10.014 · Cited by 192
Garces, F., Lee, J. H., de Val, N., Torrents de la Pena, A., Kong, L., Puchades, C., Hua, Y., Stanfield, R. L., Burton, D. R., Moore, J. P., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.11.007 · Cited by 189
Xiang, S.-H., Kwong, P. D., Gupta, R., Rizzuto, C. D., Casper, D. J., Wyatt, R., Wang, L., Hendrickson, W. A., Doyle, M. L., & Sodroski, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.19.9888-9899.2002 · Cited by 178 · cited 6×
“Thus, we conclude that the mechanism by which the different SHIV Env375 amino acid substitutions enhance rhCD4 binding is likely to be similar to that described for enhanced binding of the YU2 Env375W variant to human CD4 (25, 44, 50, 84).”
BackgroundMethodResultInfluentialSelf-citationGorman, J., Soto, C., Yang, M. M., Davenport, T. M., Guttman, M., Bailer, R. T., Chambers, M., Chuang, G.-Y., DeKosky, B. J., Doria-Rose, N. A., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3144 · Cited by 177 · cited 2×
“, CD4bs bNAb lineages by HIV-1 CH505 (53, 55, 75) or V1/V2 bNAb lineages by HIV-1 CRF_AG_250, ZM233, WITO4160, and CAP256 (88, 89)] or to elicit bNAbs in humans [e.”
BackgroundSelf-citationHaim, H., Si, Z., Madani, N., Wang, L., Courter, J. R., Princiotto, A., Kassa, A., DeGrace, M., McGee-Estrada, K., Mefford, M., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000360 · Cited by 169
Self-citationEarly development of broadly neutralizing antibodies in HIV-1–infected infants
Goo, L., Chohan, V., Nduati, R., & Overbaugh, J. (2014) · Nature Medicine · doi:10.1038/nm.3565 · Cited by 169 · cited 2×
“This strategy was used to generate SHIVs containing vpu–env(gp140) sequences from T/F HIV-1 subtype C strains CH505 and CH848 (53) and T/F subtype A strain BG505 (54).”
BackgroundMethodLi, Y., Hui, H., Burgess, C. J., Price, R. W., Sharp, P. M., Hahn, B. H., & Shaw, G. M. (1992) · Journal of Virology · doi:10.1128/jvi.66.11.6587-6600.1992 · Cited by 161
Self-citationSantra, S., Tomaras, G. D., Warrier, R., Nicely, N. I., Liao, H.-X., Pollara, J., Liu, P., Alam, S. M., Zhang, R., Cocklin, S. L., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005042 · Cited by 160 · cited 2×
“Proc Natl Acad Sci USA 107(3):1166–1171.”
Self-citationGluschankof, P., Mondor, I., Gelderblom, H. R., & Sattentau, Q. J. (1997) · Virology · doi:10.1006/viro.1997.8453 · Cited by 148
Song, R., Chenine, A.-L., Rasmussen, R. A., Ruprecht, C. R., Mirshahidi, S., Grisson, R. D., Xu, W., Whitney, J. B., Goins, L. M., Ong, H., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00558-06 · Cited by 145 · cited 1×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundPersistent infection of macaques with simian-human immunodeficiency viruses
Li, J. T., Halloran, M., Lord, C. I., Watson, A., Ranchalis, J., Fung, M., Letvin, N. L., & Sodroski, J. (1995) · Journal of Virology · doi:10.1128/jvi.69.11.7061-7067.1995 · Cited by 140 · cited 5×
“Many SHIVs derive from the original SHIV–HXBc2 construction of Sodroski and coworkers where HIV-1 HXBc2 tat, rev, and env sequences were subcloned into SIVmac239 (28, 39, 40).”
BackgroundInfluentialSelf-citationWilen, C. B., Parrish, N. F., Pfaff, J. M., Decker, J. M., Henning, E. A., Haim, H., Petersen, J., Wojcechowskyj, J. A., Sodroski, J., Haynes, B. F., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00736-11 · Cited by 140 · cited 1×
“There were also no effects of Env375 substitutions on sensitivity to T1249, which indirectly assesses fusion efficiency (63).”
BackgroundSelf-citationHaim, H., Strack, B., Kassa, A., Madani, N., Wang, L., Courter, J. R., Princiotto, A. M., Engelman, K. D., Pacheco, B., Seaman, M. S., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002101 · Cited by 125 · cited 1×
“One of these factors is the “intrinsic reactivity” or “responsiveness” of Env to CD4 engagement, which reflects the product of CD4 binding and downstream consequences of CD4 binding that allow the Env glycoprotein to negotiate transitions to lower-energy states, including those responsible for cell entry (25, 44, 50,…”
BackgroundSelf-citationQuality and quantity of T FH cells are critical for broad antibody development in SHIV AD8 infection
Yamamoto, T., Lynch, R. M., Gautam, R., Matus-Nicodemos, R., Schmidt, S. D., Boswell, K. L., Darko, S., Wong, P., Sheng, Z., Petrovas, C., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aab3964 · Cited by 117
Self-citationBannert, N., Schenten, D., Craig, S., & Sodroski, J. (2000) · Journal of Virology · doi:10.1128/jvi.74.23.10984-10993.2000 · Cited by 116 · cited 1×
“YU2 Env375S was substantially more sensitive to huCD4-Ig and rhCD4-Ig than were wild-type Env375S alleles from the other SHIVs, which is consistent with previous studies showing that YU2 Env-huCD4 affinity is high, thereby allowing it to use low levels of CD4 on human T cells, macrophages, and microglia for entry (25,…”
ResultSelf-citationLouder, M. K., Sambor, A., Chertova, E. N., Hunte, T., Barrett, S., Ojong, F., Sanders‐Buell, E., Zolla‐Pazner, S., McCutchan, F. E., Roser, J. D., et al. (2005) · Virology · doi:10.1016/j.virol.2005.06.003 · Cited by 107 · cited 1×
“Quantitative measurements of viral p27 (CA) and gp120 protein were performed by dual-color fluorescent protein gel analysis (41, 95) (SI Materials and Methods).”
MethodSelf-citationDey, B., Pancera, M., Svehla, K., Shu, Y., Xiang, S.-H., Vainshtein, J. M., Li, Y., Sodroski, J., Kwong, P. D., Mascola, J. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02500-06 · Cited by 105 · cited 1×
“Moreover, in the HIV-1 YU2 backbone, a 375W substitution for 375S allows Env to more readily sample CD4-bound conformations and enhances its affinity for human CD4 (25, 44, 49, 50).”
BackgroundSelf-citationPandrea, I., Gaufin, T., Gautam, R., Kristoff, J., Mandell, D., Montefiori, D. C., Keele, B. F., Ribeiro, R. M., Veazey, R. S., & Apetrei, C. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002170 · Cited by 98
Self-citationAlam, S. M., Liao, H., Tomaras, G. D., Bonsignori, M., Tsao, C.-Y., Hwang, K., Chen, H., Lloyd, K. E., Bowman, C. M., Sutherland, L. L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00718-12 · Cited by 97
Self-citationNishimura, Y., Shingai, M., Willey, R. L., Sadjadpour, R., Lee, W. R., Brown, C. R., Brenchley, J. M., Buckler-White, A. J., Petros, R., Eckhaus, M., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02279-09 · Cited by 88
Francica, J. R., Sheng, Z., Zhang, Z., Nishimura, Y., Shingai, M., Ramesh, A., Keele, B. F., Schmidt, S. D., Flynn, B. J., Darko, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms7565 · Cited by 88
Self-citationWalker, L. M., Sok, D., Nishimura, Y., Donau, O. K., Sadjadpour, R., Gautam, R., Shingai, M., Pejchal, R., Ramos, A. G., Simek, M. D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117531108 · Cited by 84
Prete, G. Q. D., Scarlotta, M., Newman, L. P., Reid, C., Parodi, L. M., Roser, J. D., Oswald, K. A., Marx, P. A., Miller, C. J., Desrosiers, R. C., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03507-12 · Cited by 79 · cited 5×
“Our strategy was thus to: (i) molecularly clone a new SIVmac251-derived T/F virus, pSIVmac766 (41, 42), that lacked any of four mutations found in SIVmac239 known to be suboptimal for replication (39, 43); (ii) substitute into this vector complete tat–rev–vpu–env (gp160) cassettes of T/F or primary HIV-1 strains; and…”
BackgroundMethodInfluentialSelf-citationBaalwa, J., Wang, S., Parrish, N. F., Decker, J. M., Keele, B. F., Learn, G. H., Yue, L., Ruzagira, E., Ssemwanga, D., Kamali, A., et al. (2012) · Virology · doi:10.1016/j.virol.2012.10.009 · Cited by 78 · cited 1×
“Complete tat–rev–vpu–env(gp160) cassettes from a prototypic primary subtype B strain YU2 (51) and from a genetically divergent T/F subtype D HIV-1 strain 191859 (52) were exchanged for the corresponding region of SIVmac766 (Fig.”
BackgroundSelf-citationShingai, M., Donau, O. K., Schmidt, S. D., Gautam, R., Plishka, R. J., Buckler-White, A. J., Sadjadpour, R., Lee, W. R., LaBranche, C. C., Montefiori, D. C., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217443109 · Cited by 75 · cited 1×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundSelf-citationBrown, C. R., Czapiga, M., Kabát, J., Dang, Q., Ourmanov, I., Nishimura, Y., Martin, M. A., & Hirsch, V. M. (2007) · Journal of Virology · doi:10.1128/jvi.00202-07 · Cited by 69 · cited 3×
“Three animals died of AIDS within 3 mo of infection (RM6424, RM6161, and RM6447) and were considered “rapid progressors” (67).”
BackgroundResultKassa, A., Madani, N., Schön, A., Haim, H., Finzi, A., Xiang, S.-H., Wang, L., Princiotto, A. M., Pancera, M., Courter, J. R., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00594-09 · Cited by 67 · cited 1×
“If substitution of Env375 with variant residues is the sine qua non of our SHIV design strategy, what, then, is the mechanistic basis for enhanced rhCD4 binding and cell entry? The native, unliganded HIV-1 Env trimer is conformationally flexible or “metastable” (25, 44, 49, 50, 79–81), and movement of the Env trimer f…”
BackgroundSelf-citationHumes, D. G., Emery, S., Laws, E., & Overbaugh, J. M. (2012) · Journal of Virology · doi:10.1128/jvi.02176-12 · Cited by 67 · cited 2×
“Overbaugh and coworkers (26) provided a partial molecular explanation for this inefficiency by identifying a distinguishing”
BackgroundSiddappa, N. B., Watkins, J. D., Wassermann, K. J., Song, R., Wang, W., Kramer, V. G., Lakhashe, S. K., Santosuosso, M., Poznansky, M. C., Novembre, F. J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011689 · Cited by 55 · cited 1×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundSelf-citationHaim, H., Salas, I., Engelman, K. D., Eichelberger, N., Winter, E., Pacheco, B., & Sodroski, J. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.10.006 · Cited by 52
Self-citationGautam, R., Nishimura, Y., Lee, W. R., Donau, O. K., Buckler-White, A. J., Shingai, M., Sadjadpour, R., Schmidt, S. D., LaBranche, C. C., Keele, B. F., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00644-12 · Cited by 50 · cited 1×
“Two animals (RM6069 and RM6070) died at 9 mo after infection and two others at 15 and 21 mo (RM138 and RM131), which is more typical of SIV infection (34, 67).”
BackgroundSelf-citationSelection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins
Prete, G. Q. D., Eilers, B., Moldt, B., Keele, B. F., Estes, J. D., Rodriguez, A. B., Sampias, M., Oswald, K. A., Fast, R. L., Trubey, C. M., et al. (2014) · Cell Host & Microbe · doi:10.1016/j.chom.2014.08.003 · Cited by 48
Self-citationDésormeaux, A., Coutu, M., Medjahed, H., Pacheco, B., Herschhorn, A., Gu, C., Xiang, S.-H., Mao, Y., Sodroski, J., & Finzi, A. (2012) · Journal of Virology · doi:10.1128/jvi.03104-12 · Cited by 46 · cited 4×
“Thus, we conclude that the mechanism by which the different SHIV Env375 amino acid substitutions enhance rhCD4 binding is likely to be similar to that described for enhanced binding of the YU2 Env375W variant to human CD4 (25, 44, 50, 84).”
BackgroundInfluentialSelf-citationBoyd, D. F., Peterson, D., Haggarty, B., Jordan, A. P. O., Hogan, M. J., Goo, L., Hoxie, J. A., & Overbaugh, J. M. (2014) · Journal of Virology · doi:10.1128/jvi.02680-14 · Cited by 44 · cited 1×
“The responsiveness of HIV-1 to CD4 can be altered by generic changes in Env, which also affect the sensitivity of the virus to antibody neutralization (31), or by more selective changes, as in the case of Env375 variants.”
BackgroundSiddappa, N. B., Song, R., Kramer, V. G., Chenine, A.-L., Velu, V., Ong, H., Rasmussen, R. A., Grisson, R. D., Wood, C. A., Zhang, H., et al. (2008) · Journal of Virology · doi:10.1128/jvi.02066-08 · Cited by 41 · cited 1×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundSelf-citationAdaptation of Subtype A Human Immunodeficiency Virus Type 1 Envelope to Pig-Tailed Macaque Cells
Humes, D. G., & Overbaugh, J. M. (2011) · Journal of Virology · doi:10.1128/jvi.02244-10 · Cited by 38 · cited 1×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundFinzi, A., Pacheco, B., Xiang, S.-H., Pancera, M., Herschhorn, A., Wang, L., Zeng, X., Désormeaux, A., Kwong, P. D., & Sodroski, J. (2012) · Journal of Virology · doi:10.1128/jvi.01076-12 · Cited by 36 · cited 7×
“Thus, we conclude that the mechanism by which the different SHIV Env375 amino acid substitutions enhance rhCD4 binding is likely to be similar to that described for enhanced binding of the YU2 Env375W variant to human CD4 (25, 44, 50, 84).”
BackgroundMethodResultInfluentialSelf-citationIdentification of Owl Monkey CD4 Receptors Broadly Compatible with Early-Stage HIV-1 Isolates
Meyerson, N. R., Sharma, A., Wilkerson, G. K., Overbaugh, J. M., & Sawyer, S. L. (2015) · Journal of Virology · doi:10.1128/jvi.00890-15 · Cited by 34
Ren, W., Mumbauer, A., Gettie, A., Seaman, M. S., Russell‐Lodrigue, K., Blanchard, J., Westmoreland, S. V., & Cheng‐Mayer, C. (2013) · Journal of Virology · doi:10.1128/jvi.00178-13 · Cited by 31 · cited 2×
“Other SHIV constructions have been similarly complicated (9, 18, 21, 29, 30, 32, 33).”
BackgroundGeneration and Evaluation of Clade C Simian-Human Immunodeficiency Virus Challenge Stocks
Chang, H., Tartaglia, L. J., Whitney, J. B., Lim, S., Sanisetty, S., Lavine, C. L., Seaman, M. S., Rademeyer, C., Williamson, C. E., Ellingson-Strouss, K., et al. (2014) · Journal of Virology · doi:10.1128/jvi.03279-14 · Cited by 30
Asmal, M., Luedemann, C., Lavine, C. L., Mach, L. V., Balachandran, H., Brinkley, C., Denny, T. N., Lewis, M. G., Anderson, H., Pal, R., et al. (2014) · Virology · doi:10.1016/j.virol.2014.10.032 · Cited by 28
Self-citationZhuang, K., Léda, A. R., Tsai, L., Knight, H., Harbison, C. E., Gettie, A., Blanchard, J., Westmoreland, S. V., & Cheng‐Mayer, C. (2014) · Journal of Virology · doi:10.1128/jvi.01237-14 · Cited by 27
Development of SHIV s with circulating, transmitted HIV ‐1 variants
Sharma, A., Boyd, D. F., & Overbaugh, J. M. (2015) · Journal of Medical Primatology · doi:10.1111/jmp.12179 · Cited by 22 · cited 2×
“Discussion Overbaugh and coworkers recently reviewed the history of SHIV development, the limitations of current SHIVs, and the still largely unrealized potential of SHIVs to advance vaccine, cure, and pathogenesis research (1).”
BackgroundTartaglia, L. J., Chang, H., Lee, B. C., Abbink, P., Ng’ang’a, D., Boyd, M. B., Lavine, C. L., Lim, S., Sanisetty, S., Whitney, J. B., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005431 · Cited by 21
Lopker, M. J., Prete, G. Q. D., Estes, J. D., Li, H. J., Reid, C., Newman, L. P., Lipkey, L., Camus, C., Easlick, J. L., Wang, S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00718-16 · Cited by 20
Self-citationGeneration and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides
Fennessey, C. M., Reid, C., Lipkey, L., Newman, L. P., Oswald, K. A., Piatak, M., Roser, J. D., Chertova, E. N., Smedley, J. V., Alvord, W. G., et al. (2015) · Retrovirology · doi:10.1186/s12977-015-0175-3 · Cited by 13 · cited 1×
“Our strategy was thus to: (i) molecularly clone a new SIVmac251-derived T/F virus, pSIVmac766 (41, 42), that lacked any of four mutations found in SIVmac239 known to be suboptimal for replication (39, 43); (ii) substitute into this vector complete tat–rev–vpu–env (gp160) cassettes of T/F or primary HIV-1 strains; and…”
MethodSelf-citation
Cited by
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
“In the HIV envelope, single amino acid changes are known to alter host species susceptibility (Li et al., 2016), increase expression levels (Asmal et al., 2011), change the viral phenotype from tier 2 to tier 1, cause an overall change in neutralization sensitivity (Gao et al., 2014; LaBranche et…”
Self-citationRecent progress in broadly neutralizing antibodies to HIV
Sok, D., & Burton, D. R. (2018) · Nature Immunology · doi:10.1038/s41590-018-0235-7 · Cited by 407
Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Haynes, B. F., Wiehe, K., Borrow, P., Saunders, K. O., Korber, B., Wagh, K., McMichael, A. J., Kelsoe, G., Hahn, B. H., Alt, F., et al. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00753-w · Cited by 352
Self-citationSystemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo
Nixon, C. C., Mavigner, M., Sampey, G. C., Brooks, A. D., Spagnuolo, R. A., Irlbeck, D. M., Mattingly, C., Ho, P. T., Schoof, N., Cammon, C. G., et al. (2020) · Nature · doi:10.1038/s41586-020-1951-3 · Cited by 299
Self-citationRobust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells
McBrien, J. B., Mavigner, M., Franchitti, L., Smith, S. A., White, E., Tharp, G. K., Walum, H., Busman-Sahay, K., Aguilera-Sandoval, C. R., Thayer, W. O., et al. (2020) · Nature · doi:10.1038/s41586-020-1946-0 · Cited by 187
Self-citation
Metadata
- Authors
- Li, H., Wang, S., Kong, R., Ding, W., Lee, F.-H., Parker, Z., Kim, E., Learn, G. H., Hahn, P., Policicchio, B., Brocca-Cofano, E., Deleage, C., Hao, X., Chuang, G.-Y., Gorman, J., Gardner, M., Lewis, M. G., Hatziioannou, T., Santra, S., Apetrei, C., Pandrea, I., Alam, S. M., Liao, H.-X., Shen, X., Tomaras, G. D., Farzan, M., Chertova, E., Keele, B. F., Estes, J. D., Lifson, J. D., Doms, R. W., Montefiori, D. C., Haynes, B. F., Sodroski, J. G., Kwong, P. D., Hahn, B. H., & Shaw, G. M.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2016-05-31
- Volume
- 113
- Issue
- 24
- Pages
- E3413-22
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2415277045
- Cited by
- 222
- References
- 106
- FWCI
- 16.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.